Exelixis Inc. (NASDAQ:EXEL) and Vaxart Inc. (NASDAQ:VXRT) compete against each other in the Biotechnology sector. We will compare them and contrast their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis Inc.	853.83M	8.16	690.07M	2.21	10.20
Vaxart Inc.	4.16M	3.35	18.35M	-2.47	0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 provides us Exelixis Inc. and Vaxart Inc.’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Exelixis Inc.	80.82%	75.7%	66.8%
Vaxart Inc.	-441.11%	-91%	-40.7%

Volatility and Risk

Exelixis Inc.’s current beta is 2.2 and it happens to be 120.00% more volatile than S&P 500. Vaxart Inc.’s 42.00% less volatile than S&P 500 volatility due to the company’s 0.58 beta.

Liquidity

The Current Ratio of Exelixis Inc. is 8.5 while its Quick Ratio stands at 8.4. The Current Ratio of rival Vaxart Inc. is 2 and its Quick Ratio is has 2. Exelixis Inc. is better equipped to clear short and long-term obligations than Vaxart Inc.

Analyst Ratings

Exelixis Inc. and Vaxart Inc. Ratings and Recommendations are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Exelixis Inc.	0	1	2	2.67
Vaxart Inc.	0	0	0	0.00

Exelixis Inc. has a 43.66% upside potential and a consensus price target of $33.33.

Institutional and Insider Ownership

Roughly 77.6% of Exelixis Inc. shares are held by institutional investors while 52.2% of Vaxart Inc. are owned by institutional investors. About 1.3% of Exelixis Inc.’s share are held by insiders. Competitively, 3.8% are Vaxart Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Exelixis Inc.	0.85%	-4.29%	14.4%	15.46%	-6.82%	14.69%
Vaxart Inc.	-8.74%	-18.54%	-47.81%	-45.6%	-68.49%	-11.17%

For the past year Exelixis Inc. had bullish trend while Vaxart Inc. had bearish trend.

Summary

On 12 of the 12 factors Exelixis Inc. beats Vaxart Inc.

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The companyÂ’s products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.